Wang Rui

Wangrui Biopharma is a biotechnology company based in Suzhou, China, specializing in the discovery and development of innovative peptide-based therapeutics. The company focuses on metabolic diseases, including type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH), leveraging a proprietary platform for peptide optimization and long-acting delivery. Wangrui Biopharma aims to address unmet medical needs through the development of multi-target agonists, such as GLP-1/GIP/GCG receptor co-agonists. Their pipeline includes several candidates in the pre-clinical and early discovery stages designed for improved efficacy and patient compliance.